ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype ...

With its new serum, the medical grade skin care brand is targeting laxity, which many weight loss drug users experience.

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist ...

Caution is needed until the harms are better understood Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising treatment for obesity and diabetes. Over the past few years, ...

Unless you’ve been living on another planet over the past few years, you have heard of and probably know several people that ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...